[The proapoptotic factor HLDF in the normal, hyperplastic and neoplastic endometrium].
Antibodies to the factor HLDF are shown to be specific markers of apoptosis and permit the estimation of the rate of programmed cell death in the course of a normal menstrual cycle and in pathologic endometrial processes. HLDF expression in the epitheliocytic cytoplasm makes it possible to evaluate apoptosis at early stages, before the emergence of the first morphological signs and after apoptotic body formation. The study shows increased apoptotic processes at the end of a normal menstrual cycle and during neoplastic cell transformation. Antibodies to the HLDF factor may be used as a new immunohistochemical marker for the differential diagnosis of benign and malignant endometrial processes.
Koviazin
V A
VA
Shchelokova
E E
EE
Kostanian
I A
IA
Dranitsyna
S M
SM
Frolova
I I
II
Babichenko
I I
II
D000906:Antibodies / Q000276:immunology; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis*; D004714:Endometrial Hyperplasia / Q000175:diagnosis* / Q000473:pathology; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009363:Neoplasm Proteins / Q000032:analysis*
D000906:Antibodies; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; C091149:cell differentiation factor 8.2-kDa